Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, ALT-803 and Epacadostat (QuEST1).
Phase of Trial: Phase I/II
Latest Information Update: 23 Apr 2018
At a glance
- Drugs ALT 803 (Primary) ; Epacadostat (Primary) ; MSB 0011359C (Primary) ; MVA brachyury TRICOM vaccine (Primary)
- Indications Prostate cancer; Solid tumours
- Focus Therapeutic Use
- Acronyms QuEST1
- 19 Apr 2018 Planned initiation date changed from 17 Apr 2018 to 25 Apr 2018.
- 18 Apr 2018 Status changed from not yet recruiting to recruiting.
- 13 Apr 2018 New trial record